Mingnan Chen

1.5k total citations · 1 hit paper
26 papers, 1.2k citations indexed

About

Mingnan Chen is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Mingnan Chen has authored 26 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Immunology, 12 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in Mingnan Chen's work include Immunotherapy and Immune Responses (8 papers), Immune Cell Function and Interaction (5 papers) and vaccines and immunoinformatics approaches (5 papers). Mingnan Chen is often cited by papers focused on Immunotherapy and Immune Responses (8 papers), Immune Cell Function and Interaction (5 papers) and vaccines and immunoinformatics approaches (5 papers). Mingnan Chen collaborates with scholars based in United States, China and Japan. Mingnan Chen's co-authors include Jonathan R. McDaniel, Ashutosh Chilkoti, J. Andrew MacKay, Wenge Liu, Andrew J. Simnick, Marlène Bouvier, Peng Zhao, Shuyun Dong, Jin Zhang and Xiao He and has published in prestigious journals such as Nature Materials, The EMBO Journal and Biomaterials.

In The Last Decade

Mingnan Chen

25 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Self-assembling chimeric polypeptide–doxorubicin conjugate nanoparticles that abolish tumours after a single injection

2009 500 citations J. Andrew MacKay, Mingnan Chen et al. Nature Materials profile →

Peers

Countries citing papers authored by Mingnan Chen

Since Specialization

Citations

This map shows the geographic impact of Mingnan Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mingnan Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mingnan Chen more than expected).

Fields of papers citing papers by Mingnan Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mingnan Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mingnan Chen. The network helps show where Mingnan Chen may publish in the future.

Co-authorship network of co-authors of Mingnan Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Mingnan Chen. A scholar is included among the top collaborators of Mingnan Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mingnan Chen. Mingnan Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	High-stability, low-power and broadband-spectral-response flexible carbon nanotube photoelectronic synaptic transistors modified with D-π-A-π-D photosensitive molecules 2025 ·Carbon ·Mingnan Chen, (unknown), George Z. Chen, (unknown), (unknown), Min Li, (unknown), Wanzhen Xu, (unknown)	1
2	3-in-one PD-1CAR Tregs: A bioengineered cellular therapy for target engagement, activation, and immunosuppression with reparative potential 2025 ·iScience ·Shuyun Dong, Tianxiao Zhang, Yujia Zhai, (unknown), Noel G. Carlson, John Rose, Brian D. Evavold, Mingnan Chen	0
3	Bispecific killer engager for targeted depletion of PD-1 positive lymphocytes: A new avenue for autoimmune disease treatment 2024 ·Acta Pharmaceutica Sinica B ·(unknown), Shuyun Dong, Brian D. Evavold, Xiangyang Ye, Mingnan Chen	2
4	Antibody-mediated depletion of programmed death 1-positive (PD-1+) cells 2022 ·Journal of Controlled Release ·Yujia Zhai, Shuyun Dong, Haojia Li, Yue Zhang, Paul J. Shami, Mingnan Chen	2
5	Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases 2021 ·Frontiers in Immunology ·Yujia Zhai, (unknown), Mingnan Chen	25
6	Promotion of CTL epitope presentation by a nanoparticle with environment-responsive stability and phagolysosomal escape capacity 2020 ·Journal of Controlled Release ·Shuyun Dong, Sundharraman Subramanian, Kristin N. Parent, Mingnan Chen	2
7	Depletion of PD-1-positive cells ameliorates autoimmune disease 2019 ·Nature Biomedical Engineering ·Peng Zhao, Peng Wang, Shuyun Dong, (unknown), Yanguang Cao, Hideo Yagita∥, Xiao He, Song Guo Zheng, Simon J. Fisher, Robert S. Fujinami, Mingnan Chen	58
8	Exploring the Influence Mechanism of Meteorological Conditions on the Concentration of Suspended Solids and Chlorophyll-a in Large Estuaries Based on MODIS Imagery 2019 ·Water ·Cheng He, Youru Yao, (unknown), Mingnan Chen, Weichun Ma, Liguo Zhou	6
9	Direct loading of CTL epitopes onto MHC class I complexes on dendritic cell surface in vivo 2018 ·Biomaterials ·Peng Wang, Shuyun Dong, Peng Zhao, Xiao He, Mingnan Chen	12
10	An Albumin-binding Polypeptide Both Targets Cytotoxic T Lymphocyte Vaccines to Lymph Nodes and Boosts Vaccine Presentation by Dendritic Cells 2017 ·Theranostics ·Peng Wang, Peng Zhao, Shuyun Dong, Tiefeng Xu, Xiao He, Mingnan Chen	28
11	Engineering of a self-adjuvanted iTEP-delivered CTL vaccine 2017 ·Acta Pharmacologica Sinica ·Shuyun Dong, Tiefeng Xu, Peng Wang, Peng Zhao, Mingnan Chen	6
12	An iTEP-salinomycin nanoparticle that specifically and effectively inhibits metastases of 4T1 orthotopic breast tumors 2016 ·Biomaterials ·Peng Zhao, (unknown), Shuyun Dong, Zhong‐Xing Jiang, Mingnan Chen	32
13	A Comparison Study of iTEP Nanoparticle-Based CTL Vaccine Carriers Revealed a Surprise Relationship between the Stability and Efficiency of the Carriers 2016 ·Theranostics ·Shuyun Dong, Tiefeng Xu, Peng Zhao, Kristin N. Parent, Mingnan Chen	9
14	Doxorubicin-conjugated polypeptide nanoparticles inhibit metastasis in two murine models of carcinoma 2015 ·Journal of Controlled Release ·Eric M. Mastria, Mingnan Chen, Jonathan R. McDaniel, Xinghai Li, Jinho Hyun, Mark W. Dewhirst, Ashutosh Chilkoti	48
15	Gene-Directed Enzyme Prodrug Therapy 2014 ·The AAPS Journal ·Jin Zhang, (unknown), Mingnan Chen	117
16	NANOSCALE SELF-ASSEMBLY FOR DELIVERY OF THERAPEUTICS AND IMAGING AGENTS 2011 ·Technology & Innovation ·Mingnan Chen, Jonathan R. McDaniel, J. Andrew MacKay, Ashutosh Chilkoti	4
17	Injectable intratumoral depot of thermally responsive polypeptide–radionuclide conjugates delays tumor progression in a mouse model 2010 ·Journal of Controlled Release ·Wenge Liu, J. Andrew MacKay, Matthew R. Dreher, Mingnan Chen, Jonathan R. McDaniel, Andrew J. Simnick, Daniel J. Callahan, Michael R. Zalutsky, Ashutosh Chilkoti	81
18	Self-assembling chimeric polypeptide–doxorubicin conjugate nanoparticles that abolish tumours after a single injection breakdown → 2009 ·Nature Materials ·J. Andrew MacKay, Mingnan Chen, Jonathan R. McDaniel, Wenge Liu, Andrew J. Simnick, Ashutosh Chilkoti	500
19	The convergent roles of tapasin and HLA-DM in antigen presentation 2008 ·Trends in Immunology ·Scheherazade Sadegh‐Nasseri, Mingnan Chen, Kedar Narayan, Marlène Bouvier	33
20	Analysis of interactions in a tapasin/class I complex provides a mechanism for peptide selection 2007 ·The EMBO Journal ·Mingnan Chen, Marlène Bouvier	138

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact